Chemo's hidden heart risk: study probes Cisplatin's effect on blood vessels
NCT ID NCT01453660
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study looks at how the chemotherapy drug cisplatin affects the inner lining of blood vessels (the endothelium) in men with germ cell tumors. Researchers will measure blood vessel function in patients receiving cisplatin and compare them to a group who had surgery only. The goal is to better understand the link between cisplatin and long-term heart disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cisplatin chemotherapy
- What this could lead to
- If successful, this study could help explain how cisplatin causes long-term heart problems and point to ways to prevent them.
- What could go wrong
- This is a small, early pilot study that only measures short-term changes. It may not prove a clear link or lead to any new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 44 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2011
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The Cisplatin-Based Chemotherapy Group will be recruited from the Genitourinary (GU) oncology clinics. The GU Oncology section has a large clinical service which ensures adequate recruitment. The Surgery-Only Group will consist of patients with a diagnosis of GCT who have recently had surgical management of their disease and are not planned to receive radiation or chemotherapy. Potentially eligible patients will be recruited from the GU Oncology and Urology clinics since they are seen by both services.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Cisplatin-Based Chemotherapy Group * Histologically-proven diagnosis of GCT * Male * Age ≥18 * No prior exposure to chemotherapy or radiation * Planned to receive 3-4 cycles of cisplatin-based chemotherapy Surgery-Only Group * Histologically-proven diagnosis of GCT Male * Age ≥18 * Surgical management of GCT performed less than 90 days before start of study (includes orchiectomy and primary retroperitoneal lymph node dissection (RPLND)) * No prior exposure to chemotherapy or radiation Exclusion Criteria: Cisplatin-Based Chemotherapy Group * Prior exposure to chemotherapy or radiation * Known diagnosis or history of being diagnosed with vasculitis, autonomic dysfunction, coronary artery disease, or collagen-vascular disease Surgery-Only Group * Prior exposure to chemotherapy or radiation * Planned for non-surgical management with chemotherapy or radiation. * Known diagnosis or history of being diagnosed with vasculitis, autonomic dysfunction, coronary artery disease, or collagen-vascular disease.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Germ cell cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.